TIME HALL A
09:30 – 11:00 ACUTE MYELOID LEUKEMIA

Scientific Chair: İnci Alacacıoğlu (Dokuz Eylül University, Turkey), Hartmut Döhner (University of Ulm Germany)
Molecular Heterogeneity and Clonal Evolution of AML: Lars Bullinger (Charité Universitätsmedizin Berlin, Germany)
Combining New Agents with “3+7“ Chemotherapy in Fit Patients: Hartmut Döhner (University of Ulm, Germany)
New Agents For The Treatment of Older Patients: Andrew Wei (Alfred Hospital, Melbourne, Australia)

11:00 – 11:30 BREAK
11:30 – 13:00 CHRONIC LYMPHOCYTIC LEUKEMIA
Scientific Chair: Fatih Demirkan (Dokuz Eylül University, Turkey)Michael Hallek (University Hospital of Cologne, Germany)
State-of-the Art First Line Therapy of CLL: Michael Hallek (University Hospital of Cologne, Germany)
Management of Relapsed CLL and Richter Transformation: Davide Rossi (Institute of Oncology Research, Switzerland)
Modelling of Response Pattern and Cloned Evolution of CLL: Othman Al-Sawaf (University Hospital of Cologne, Germany)
13:00 – 13:30 BREAK
13:30 -14:15

Abbvie | Brands of the World™ | Download vector logos and logotypesSATELLITE SYMPOSIUM
The Evolving Role of Venetoclax in the Era of Novel R/R CLL Therapies

Scientific Chair: Burhan Ferhanoğlu (Koç University, Turkey)
Speaker: Michael Hallek (University Hospital of Cologne, Germany)

14:15 – 14:45 BREAK
14:45- 16:15 HODGKIN LYMPHOMA
Scientific Chair: Muhit Özcan (Ankara University, Turkey), Bastian von Tresckow (University Hospital Essen, Germany)
Firstline Treatment of HL: Paul Bröckelmann (University Hospital of Cologne, Germany)
Update on NLPHL: Dennis Eichenauer (University Hospital of Cologne, Germany)
Relapsed and Refractory HL: Innovative Therapies: Bastian von Tresckow (University Hospital Essen , Germany)
16:15 – 16:45 BREAK
16:45 – 17:30

SATELLITE SYMPOSIUM

Optimizing Outcomes for Patients with CLL in 2021: Challenging the Genetics

Scientific Chair: Ahmet Muzaffer Demir (Trakya University, Turkey)
How Biology is Informing Treatment Decisions in Firstline CLL ?: Fatih Demirkan (Dokuz Eylül University, Turkey)
Breakthrough CLL Disease Control in Relapsed  & Refractory Settings: Long Term Ibrutinib Outcomes: Önder           
      Arslan (Ankara University, Turkey)
 

17:30 – 18:00 BREAK
18:00 – 19:30 ACUTE LYMPHOBLASTIC LEUKEMIA
Scientific Chair: Önder Arslan (Ankara University, Turkey), Dieter Hoelzer (Goethe University of Frankfurt, Germany)
Immunotherapies in B-Lineage ALL: Dieter Hoelzer (Goethe University of Frankfurt, Germany)
Current Status and Future Prospects in T-ALL: Nicolas Boissel (Hôpital Saint-Louis, France)
Progress in Ph+/Ph-like ALL: Oliver Ottmann (Cardiff University, Wales)
19:30 – 20:00 BREAK
20:00 – 21:30 AGGRESSIVE LYMPHOMAS
Scientific Chair: Burhan Ferhanoğlu (Koç University, Turkey)Martin Dreyling (Munich University, Germany)
Primary CNS Lymphoma: Andres Ferreri (Vita-Salute San Raffaele University, Italy)
Mantle Cell Lymphoma: Martin Dreyling (Munich University, Germany)
CAR T-Cells in DLBCL: Marion Subklewe (Gene Center, Germany)
21:30 – 21:45 BREAK
21:45 – 22:00 Closing Remarks